NCT05927571 2026-03-05A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)Genentech, Inc.Phase 1 Recruiting120 enrolled
NCT05972135 2026-02-23Outpatient Administration of Teclistamab or Talquetamab for Multiple MyelomaSCRI Development Innovations, LLCPhase 2 Recruiting100 enrolled
NCT06251076 2025-12-10Plan Development for Giving Teclistamab in the Outpatient SettingUniversity Health Network, TorontoPhase 4 Recruiting15 enrolled